Xiaohui He

Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

Wenfeng Fang, Yunpeng Yang, Yuxiang Ma et al. · The Lancet Oncology · 2018 · 495 citations

Medicine, Immunology, Pathology +8

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 429 citations

Medicine, Clinical Trials, Immune Checkpoint Inhibitor +8

Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen et al. · Nature Medicine · 2021 · 387 citations

Oncology, Metronomic Therapy, Nasopharyngeal Cancer +7

Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma

Ye‐Xiong Li, Bo Yao, Jing Jin et al. · Journal of Clinical Oncology · 2005 · 357 citations

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Hai‐Qiang Mai, Qiuyan Chen, Dongping Chen et al. · JAMA · 2023 · 196 citations · Full text